

P P Q P S R P A P P P A P P S	16
cgccgcccgcagccttctcggcccgcccccgcgcctgcacccccatct	50
A L P R G G <u>R A A R</u> A G G P G S R	33
gctcttccccgcgggggcccgcggcgccgggtgggggcccgggcagccg	100
A R A A G A R G C R L R S Q L V	49
cgctcgggcagcgggggscgcggggctgccgcctgcgctcgcagctgggtgc	150
P V R A L G L G H R S D E L V R P	66
cgggtgcgcgcgctcggcctggggccaccgctccgacgagctggcggttc	200
R F C S G S C R R A R S P H D L S	83
cgcttctgcagcggctcctgccgcgcgcgcgtctccacacgacctcag	250
L A S L L G A G A L R P P P G S	99
cctggccagcctactgggcgcgggggcccctgcgaccgccccgggtccc	300
R P V S Q P C C R P T R Y E A V S	116
ggcccgctcagccagccctgctgccgacccacgcgctacgaagcgggtctcc	350
F M D V <u>N S T</u> W R T V D R L S A T	133
ttcatggacgtcaacagcacctggagaaccgtggaccgcctctccgccac	400
A C G C L G *	139
cgcctgcgggctgcctgggctgagggctcgctccagggtttgcagactgg	450
acccttaaccgggtgggtctctccctgc	474

Figure 1

hGDNF : SPDKQAVLPFRERNRQAAAAANPENSRCGRGGRGKNGCVITAIHNVTDLGLGYETRELEFRYCSG : 70  
 hNTN : -----ARLQAPCGLEPEVRVSEGLGCTSEETVLFYCYG : 37  
 hPSP : -----ELSGPQOWSETISVAELGLGYSECVLFYCYG : 35  
 hEVN : -----AGCPGSEARAARNGYRIRVQLVPVRAIGLGRSEELVRFETSS : 45

\* \* \*  
 hGDNF : SCDA-PETTYOKIINKESRNRRVVS-----DKYSAACNRIEFDDELSTUDNLLVYELERKESAKRCCCI- : 134  
 hNTN : ACSE-AARVYDLGRRRQRRER-----ENVRAADTCNRTIYSEVVSFLDAHSEYVHELSARECAGV- : 102  
 hPSP : SCPRGAPTEONGLAERLOGOE-----NAHCGPCCRPTRT-EVAGLUDRHSEORHPQLSAARCCGGG : 96  
 hEVN : SCRR-ARSPDLSLESGLGAGARPPFGSPESOPCCNITRM-ANSEMNVNSTRBTVDRLSRTCCGLG : 113


Figure 2

604720-04E25E60


<b>reading frame A</b>	<b>M P G L I S A</b>	<b>7</b>
gagttttccctccacacagctaggagcccatgcccggcctgatctcagcc		50
<b>R G Q P L L E V L P P Q A H L G A</b>		<b>24</b>
cgaggacagccctccttgaggctccttcccccagccacctgggtgc		100
<b>L F L P E A P L G L S A Q P A L</b>		<b>A40</b>
cctcttttctccctgaggctccacttggtctctccgcgcagcctgccctgt		150
<b>W P T L A A L A L L S S V A E A S</b>		<b>A57</b>
ggccaccctggcgcctctgggtctgtgtgagcagcgtcgcagaggcctcc		200
<b>L G S A P R S P A P R E G F P P V</b>		<b>A74</b>
ctgggtccgcgccccgcagccctgccccccggaaggccccccgcctgt		250
<b>L A S P A G H L P G R *</b>		<b>A85</b>
cctggcgtcccccgccggccacctgccgggtagggtgagagggcgaggggg		300
<b>reading frame B</b>	<b>* L G L I P G</b>	<b>B6</b>
cgggggcggggctggcccgggacaccgcgcgtgactgggtctcattccagg		350
<b>G R T A R W C S G R A R R P P P</b>		<b>B22</b>
gggacgcacggcccgctgggtgcagtggaagagcccgggcgccgcgcgc		400
<b>Q P S R P A F P P P A P P S A L P</b>		<b>B39</b>
agccttctcgggcccg-gccccgcgcctgcacccccatctgtctttccc		450
<b>R G G <u>R A A R</u> A G G P G S R A R A</b>		<b>B56</b>
cg-cggggggcgcgcgggcggggtggggggccggggcagccgcgctcgggc		500
<b>A G A R G C R L R S Q L V P V R</b>		<b>B72</b>
agcggggggcgcggggctgccgcctgcgcctgcagctggtgcccgggtgcgcg		550
<b>A L G L G H R S D E L V R F R F C</b>		<b>B89</b>
cgtctgggcctggggccaccgctccgaagagctgggtgcgtttccgcttctgc		600
<b>S G S C R R A R S F H D L S L A S</b>		<b>B106</b>
agcggctcctgccgcgcgcgcgtctccacacgacctcagcctggccag		650
<b>L L G A G A L R P P P G S R P V</b>		<b>B122</b>
cctactgggcgcgggggcccctgcgaccgccccgggctcccggcccgctca		700
<b>S Q P C C R P T R Y E A V S F M D</b>		<b>B139</b>
gccagccctgctgccgaccacgcgctacgaagcgggtctccttcatggac		750
<b>V <u>N S T</u> W R T V D R L S A T A C G</b>		<b>B156</b>
gtcaacagcacctggagaaccgtggaccgcctctccgccaccgcctgcgg		800
<b>C L G *</b>		<b>B159</b>
ctgcctggggctgagggctc		819

Figure 3

6447420-6448360



**Figure 4B**



CONFIDENTIAL

Figure 5

A

Heart  
Brain  
Placenta  
Lung  
Liver  
Skel. muscle  
Kidney  
Pancreas


9.5 kb  
7.5 kb  
4.4 kb  
2.4 kb  
1.35 kb



B

Spleen  
Thymus  
Prostate  
Testis  
Ovary  
Small intestine  
Colon  
Peripheral blood leukocytes

9.5 kb  
7.5 kb  
4.4 kb  
2.4 kb  
1.35 kb




C

Kidney  
Liver  
Lung  
Brain

9.5 kb  
7.5 kb  
4.4 kb  
2.4 kb  
1.35 kb



[illegible]

## EXP 1356: XTT na 72h




Figure 6



63720-07E-000




Figure 7

# The Effects of Enovin on Proliferation Rate of Human Dermal Fibroblast Cells (39SK) (one-day-treatment)




Figure 8

00257349-071499

# The Effect of Enovin on Proliferation Rate of Human Dermal Fibroblast Cells (39SK) (three-day-treatment)




Figure 9

**Figure 1**

# The Effects of Enovin on Proliferation Rate of Human Chondrocytes (two-day-treatment)




Figure 1C

002457249 024499

## Derma! Fibroblasts

[illegible]

# The Effects of Enovin on Proliferation Rate of Human Umbilical Vein Endothelial Cells (HUVEC) (one-day-treatment)




Figure 12



# Vein Endothelial Cells

[illegible]



# The Effects of Enovin on Proliferation Rate of Rat Osteoblasts (one-day-treatment)




Figure 15

# The Effects of Enovin on Proliferation Rate of Human Smooth Muscle Cells (SMC) (one-day-treatment)




Figure 16

09357349-071499

# The Effects of Enovin on Proliferation Rate of Human Smooth Muscle Cells (SMC) (three-day-treatment)




Figure 17

Figure 1. The effect of the number of iterations on the accuracy of the proposed algorithm. The accuracy is measured by the number of correct elements in the solution set. The number of iterations is 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, 5000, 5100, 5200, 5300, 5400, 5500, 5600, 5700, 5800, 5900, 6000, 6100, 6200, 6300, 6400, 6500, 6600, 6700, 6800, 6900, 7000, 7100, 7200, 7300, 7400, 7500, 7600, 7700, 7800, 7900, 8000, 8100, 8200, 8300, 8400, 8500, 8600, 8700, 8800, 8900, 9000, 9100, 9200, 9300, 9400, 9500, 9600, 9700, 9800, 9900, 10000. The accuracy is 0.0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0.

**by one-day-treatment)**




Figure 18

667620-64E25E00

### Reversal of taxol-induced sensory deficits




Fig 19

# Prevention of taxol-induced sensory deficits




Fig 20

M E L G L G G L S T L 11  
 1 CTGATGGGCGCTCCTGGTGTGATAGAGATGGAACCTTGGACTTGGAGGCCTCTCCACGCT  
 S H C P W P R R Q (5'-3') 20  
 61 GTCCCACTGCCCTGGCCTAGGCGGCAGGTGAGTGGTTCTCCAGTGACTCCTACCTGGT  
 121 ACTGAGGAAAGGCGGCTTGAAGTGGTGGAGGAGAGAGGGCTTGGCTTGGGCAGCGGTTAG  
 181 GTGTGGGAGGGAAAATGGTCAGGGAGGGACCAGGTGAATGGGAGGAGGAGCGGGACTTCT  
 241 CTGAATGGTCGGTGCACCTCAGGTGATTCTCCCTGGGCTCCAGAGGCAGCAAACCCAT  
 301 TATACTGGAACCTAGGCCCTTCTGAGTTTCCCTCCACACAGCTAGGAGCCCATGCCCCG  
 361 GCCTGATCTCAGCCCGAGGACAGCCCTCCTTGAGGTCCTTCCCTCCCAAGCCACCTGG  
 (3'-3') (3'-2)  
 421 GTGCCCTCTTTCTCCCTGAGGCTCCACTTGGTCTCTCCGCGCAGCCTGCCCTGTGGCCCA 33  
 A P L G L S A Q P A L W P  
 T L A A L A L L S S V A E A S L G S A P 53  
 481 CCCTGGCCGCTCTGGCTCTGCTGAGCAGCGTCGAGAGGCCCTCCCTGGGCTCCGCGCCCC  
 R S P A P R E G P P P V L A S P A G H L 73  
 541 GCAGCCCTGCCCCCGCGAAGGCCCCCGCCTGTCTGGCGTCCCCCGCGGCCACCTGC  
 (5'-2)  
 P 74  
 601 CGGCTAGGTGAGAGGGCGAGGGGGCGGGGCGGGGCTGGCCCGGACACCGCGCGTGACTG  
 (3'-3)  
 G G R T A R W C S G R A R R P P 90  
 661 GGTCTCATTCCAGGGGACGCACGGCCCGCTGGTGCAGTGAAGAGCCCGGCGGCCGCCG  
 P Q P S R P A P P P P A P P S A L P R G 110  
 721 CCGCAGCCTTCTCGGCCGCGCCCCCGCGCCTGCACCCCATCTGCTCTTCCCCGCGGG  
 G R A A R A G G P G S R A R A A G A R G 130  
 781 GGCCGCGCGGCGCGGCTGGGGGCCCCGGGAGCCGCGCTCGGGCAGCGGGGGCGCGGGG  
 C R L R S Q L V P V R A L G L G H R S D 150  
 841 TGCCGCTGCGCTCGCAGCTGGTGCCGGTGCGCGCGCTCGGCCTGGGCCACCGCTCCGAC  
 (3'-4)  
 E L V R F R F C S G S C R R A R S P H D 170  
 901 GAGCTGGTGCCTTCCGCTTCTGCAGCGGCTCCTGCCGCGCGCGCTCTCCACACGAC  
 L S L A S L L G A G A L R P P P G S R P 190  
 961 CTCAGCCTGGCCAGCCTACTGGGCGCCGGGGCCCTGCGACCGCCCCGGGCTCCCGGCC  
 V S Q P C C R P T R Y E A V S F M D V N 210  
 1021 GTCAGCCAGCCCTGCTGCCGACCCACGCGCTACGAAGCGGTCTCCTTCATGGACGTCAAC  
 S T W R T V D R L S A T A C G C L G \* 228  
 1081 AGCACCTGGAGAACCGTGGACCGCCTCTCCGCCACCGCCTGCGGCTGCCTGGGCTGAGGG  
 1141 CTCGCTCCAGGGCTTTGCAGACTGGACCCTTACCGGTGGCTCTTCTG




Fig 22




[illegible]

Figure 23

1 MELGLGGLST LSHCPWPRRQ PALWPTLAAL ALLSSVAEAS LGSAPRSPAP  
51 REGPPFVLAS PAGHLPGGRT ARWCSGRARR PPPQPSRPAP PPPAPPSALP  
101 RGGRAARAGG PGSRARAAGA RGCLRSQLV PVRALGLGHR SDELVRFRFC  
151 SGSCRRARSP HDLSLASLLG AGALRPPPGS RPVSQPCCRP TRYEAVSFMD  
201 VNSTWRTVDR LSATACGCLG

Figure 24

## Erythroid and GADH expression in multiple sclerosis and Alzheimer's disease



Adjusted SD were calculated using Q1 values and 3rd quartile values. On P-values comparisons were done by ANOVA analysis.

**• editors to delete only what's not**

Figure 25

**Brain expression in Parkinson's disease**

Genes: P-004, P-008, P-009, P-010

Brain tissue: substantia nigra, putamen, globus pallidus

**Brain expression in cancer**

Genes: P-004, P-008, P-009, P-010

Brain tissue: substantia nigra, putamen, globus pallidus

# Introduction